1 | standardized | 7,530 |
2 | standardised | 2,215 |
3 | study-specific | 113 |
4 | 15-item | 58 |
5 | forced-choice | 46 |
6 | pre-designed | 34 |
7 | predesigned | 29 |
8 | bespoke | 23 |
9 | nine-item | 23 |
10 | nonstandardized | 20 |
11 | purpose-designed | 20 |
12 | non-standardised | 18 |
13 | self-developed | 18 |
14 | self-made | 17 |
15 | hospital-specific | 15 |
16 | 23-item | 13 |
17 | prerecorded | 13 |
18 | 33-item | 12 |
19 | precoded | 12 |
20 | non-emotional | 11 |
21 | semi-standardised | 9 |
22 | stamping | 9 |
23 | pre-piloted | 8 |
24 | levels-of-evidence | 6 |
25 | pre-developed | 6 |
26 | blunt-tipped | 5 |
27 | db-im | 5 |
28 | milliplex | 5 |
29 | six-field | 5 |
30 | two-round | 5 |
31 | ward-specific | 5 |
32 | 13-point | 4 |
33 | ad-ssa | 4 |
34 | comorbidity-adapted | 4 |
35 | double-pulse | 4 |
36 | nonoptimized | 4 |
37 | prestructured | 4 |
38 | self-formulated | 4 |
39 | 'stupp | 3 |
40 | 26-element | 3 |
41 | cell-tracking | 3 |
42 | dsm-based | 3 |
43 | low-antigen-content | 3 |
44 | n2o-free | 3 |
45 | pondr-fit | 3 |
46 | self-leveling | 3 |
47 | smooth-edged | 3 |
48 | specifically-designed | 3 |
49 | workstation-based | 3 |
50 | 16-minute | 2 |
51 | 2.9-year | 2 |
52 | 3-stimulus | 2 |
53 | amydriatic | 2 |
54 | child-completed | 2 |
55 | cross-sector | 2 |
56 | crp-guided | 2 |
57 | dexmedetomidine-based | 2 |
58 | dixon-massey | 2 |
59 | four-course | 2 |
60 | haake | 2 |
61 | heinous | 2 |
62 | hpufsh-gnrhant | 2 |
63 | i-tasser | 2 |
64 | ml21445 | 2 |
65 | natural-language | 2 |
66 | no-limitation | 2 |
67 | nomogram-a | 2 |
68 | nonsuggestive | 2 |
69 | nurse-supervised | 2 |
70 | pre-teaching | 2 |
71 | pregenerated | 2 |
72 | relaxant-free | 2 |
73 | ses-specific | 2 |
74 | split-shipment | 2 |
75 | t2-preparation | 2 |
76 | veratox | 2 |
77 | 1.2-kg | 1 |
78 | 1.7-kg | 1 |
79 | 12236 | 1 |
80 | 13.4-year | 1 |
81 | 130-bed | 1 |
82 | 2-day-longer | 1 |
83 | 270-beds | 1 |
84 | 300-mas | 1 |
85 | 37-minute | 1 |
86 | 4.46-mg/dl | 1 |
87 | 43-month | 1 |
88 | 45-years-old | 1 |
89 | 5.23-6.80 | 1 |
90 | 51-minute | 1 |
91 | 53-day-old | 1 |
92 | 64-yr-old | 1 |
93 | 68,045 | 1 |
94 | activity-recognition | 1 |
95 | anatomical-therapeutic-chemical/ddd | 1 |
96 | apredesigned | 1 |
97 | artequin | 1 |
98 | baroda | 1 |
99 | block-and-release | 1 |
100 | blockmatching | 1 |
101 | call.imaging | 1 |
102 | cd71-mediated | 1 |
103 | contraction-onabotulinumtoxina | 1 |
104 | controlled-challenge | 1 |
105 | cvt/sct/ispe | 1 |
106 | cyclotron-produced | 1 |
107 | dbcg-82tm | 1 |
108 | deception-detection | 1 |
109 | diameter-based | 1 |
110 | divi-emergency | 1 |
111 | drug-in-food | 1 |
112 | dual-imaging | 1 |
113 | dynamic-ecg | 1 |
114 | empty-and-fill | 1 |
115 | en-14175 | 1 |
116 | fatigue-producing | 1 |
117 | fixed-parameter | 1 |
118 | galectin-9-sensitive | 1 |
119 | gemfibrocyl-treated | 1 |
120 | gp5+6+ | 1 |
121 | gt/profile | 1 |
122 | habituation-based | 1 |
123 | ich-compliant | 1 |
124 | ifosfamide-carboplatin-etoposide | 1 |
125 | intraexperimental | 1 |
126 | laporatomy | 1 |
127 | limited-options | 1 |
128 | macrocephalic | 1 |
129 | magnet-treatment | 1 |
130 | manufacturer-created | 1 |
131 | merica | 1 |
132 | meropenem-treated | 1 |
133 | mg-enabled | 1 |
134 | midcourse | 1 |
135 | multi-ethnical | 1 |
136 | multicultural/multiracial | 1 |
137 | multiple-handicapped | 1 |
138 | munich-composite | 1 |
139 | nora-based | 1 |
140 | nutraceutical-based | 1 |
141 | odd-impact | 1 |
142 | patient-access | 1 |
143 | pedophilic | 1 |
144 | pet/ct-mr | 1 |
145 | publicly-registered | 1 |
146 | race/niti | 1 |
147 | ramp-test | 1 |
148 | rest-to-stand | 1 |
149 | self-tabulate | 1 |
150 | senieur | 1 |
151 | short-injection-duration | 1 |
152 | shrimp-allergic | 1 |
153 | slow-cooling | 1 |
154 | social-marketing-based | 1 |
155 | stigma-associated | 1 |
156 | stress-redistribution-reinjection | 1 |
157 | surface-doping | 1 |
158 | takla-o'donnell | 1 |
159 | thromboelastography-based | 1 |
160 | triple-scan | 1 |
161 | tuberculosis-like | 1 |
162 | turnkey | 1 |
163 | two-limbed | 1 |
164 | verbal-feedback | 1 |
165 | voice-over-internet | 1 |
1 | 'stupp | 3 |
2 | 1.2-kg | 1 |
3 | 1.7-kg | 1 |
4 | 12236 | 1 |
5 | 13-point | 4 |
6 | 13.4-year | 1 |
7 | 130-bed | 1 |
8 | 15-item | 58 |
9 | 16-minute | 2 |
10 | 2-day-longer | 1 |
11 | 2.9-year | 2 |
12 | 23-item | 13 |
13 | 26-element | 3 |
14 | 270-beds | 1 |
15 | 3-stimulus | 2 |
16 | 300-mas | 1 |
17 | 33-item | 12 |
18 | 37-minute | 1 |
19 | 4.46-mg/dl | 1 |
20 | 43-month | 1 |
21 | 45-years-old | 1 |
22 | 5.23-6.80 | 1 |
23 | 51-minute | 1 |
24 | 53-day-old | 1 |
25 | 64-yr-old | 1 |
26 | 68,045 | 1 |
27 | activity-recognition | 1 |
28 | ad-ssa | 4 |
29 | amydriatic | 2 |
30 | anatomical-therapeutic-chemical/ddd | 1 |
31 | apredesigned | 1 |
32 | artequin | 1 |
33 | baroda | 1 |
34 | bespoke | 23 |
35 | block-and-release | 1 |
36 | blockmatching | 1 |
37 | blunt-tipped | 5 |
38 | call.imaging | 1 |
39 | cd71-mediated | 1 |
40 | cell-tracking | 3 |
41 | child-completed | 2 |
42 | comorbidity-adapted | 4 |
43 | contraction-onabotulinumtoxina | 1 |
44 | controlled-challenge | 1 |
45 | cross-sector | 2 |
46 | crp-guided | 2 |
47 | cvt/sct/ispe | 1 |
48 | cyclotron-produced | 1 |
49 | db-im | 5 |
50 | dbcg-82tm | 1 |
51 | deception-detection | 1 |
52 | dexmedetomidine-based | 2 |
53 | diameter-based | 1 |
54 | divi-emergency | 1 |
55 | dixon-massey | 2 |
56 | double-pulse | 4 |
57 | drug-in-food | 1 |
58 | dsm-based | 3 |
59 | dual-imaging | 1 |
60 | dynamic-ecg | 1 |
61 | empty-and-fill | 1 |
62 | en-14175 | 1 |
63 | fatigue-producing | 1 |
64 | fixed-parameter | 1 |
65 | forced-choice | 46 |
66 | four-course | 2 |
67 | galectin-9-sensitive | 1 |
68 | gemfibrocyl-treated | 1 |
69 | gp5+6+ | 1 |
70 | gt/profile | 1 |
71 | haake | 2 |
72 | habituation-based | 1 |
73 | heinous | 2 |
74 | hospital-specific | 15 |
75 | hpufsh-gnrhant | 2 |
76 | i-tasser | 2 |
77 | ich-compliant | 1 |
78 | ifosfamide-carboplatin-etoposide | 1 |
79 | intraexperimental | 1 |
80 | laporatomy | 1 |
81 | levels-of-evidence | 6 |
82 | limited-options | 1 |
83 | low-antigen-content | 3 |
84 | macrocephalic | 1 |
85 | magnet-treatment | 1 |
86 | manufacturer-created | 1 |
87 | merica | 1 |
88 | meropenem-treated | 1 |
89 | mg-enabled | 1 |
90 | midcourse | 1 |
91 | milliplex | 5 |
92 | ml21445 | 2 |
93 | multi-ethnical | 1 |
94 | multicultural/multiracial | 1 |
95 | multiple-handicapped | 1 |
96 | munich-composite | 1 |
97 | n2o-free | 3 |
98 | natural-language | 2 |
99 | nine-item | 23 |
100 | no-limitation | 2 |
101 | nomogram-a | 2 |
102 | non-emotional | 11 |
103 | non-standardised | 18 |
104 | nonoptimized | 4 |
105 | nonstandardized | 20 |
106 | nonsuggestive | 2 |
107 | nora-based | 1 |
108 | nurse-supervised | 2 |
109 | nutraceutical-based | 1 |
110 | odd-impact | 1 |
111 | patient-access | 1 |
112 | pedophilic | 1 |
113 | pet/ct-mr | 1 |
114 | pondr-fit | 3 |
115 | pre-designed | 34 |
116 | pre-developed | 6 |
117 | pre-piloted | 8 |
118 | pre-teaching | 2 |
119 | precoded | 12 |
120 | predesigned | 29 |
121 | pregenerated | 2 |
122 | prerecorded | 13 |
123 | prestructured | 4 |
124 | publicly-registered | 1 |
125 | purpose-designed | 20 |
126 | race/niti | 1 |
127 | ramp-test | 1 |
128 | relaxant-free | 2 |
129 | rest-to-stand | 1 |
130 | self-developed | 18 |
131 | self-formulated | 4 |
132 | self-leveling | 3 |
133 | self-made | 17 |
134 | self-tabulate | 1 |
135 | semi-standardised | 9 |
136 | senieur | 1 |
137 | ses-specific | 2 |
138 | short-injection-duration | 1 |
139 | shrimp-allergic | 1 |
140 | six-field | 5 |
141 | slow-cooling | 1 |
142 | smooth-edged | 3 |
143 | social-marketing-based | 1 |
144 | specifically-designed | 3 |
145 | split-shipment | 2 |
146 | stamping | 9 |
147 | standardised | 2,215 |
148 | standardized | 7,530 |
149 | stigma-associated | 1 |
150 | stress-redistribution-reinjection | 1 |
151 | study-specific | 113 |
152 | surface-doping | 1 |
153 | t2-preparation | 2 |
154 | takla-o'donnell | 1 |
155 | thromboelastography-based | 1 |
156 | triple-scan | 1 |
157 | tuberculosis-like | 1 |
158 | turnkey | 1 |
159 | two-limbed | 1 |
160 | two-round | 5 |
161 | veratox | 2 |
162 | verbal-feedback | 1 |
163 | voice-over-internet | 1 |
164 | ward-specific | 5 |
165 | workstation-based | 3 |
1 | gp5+6+ | 1 |
2 | 5.23-6.80 | 1 |
3 | 68,045 | 1 |
4 | ml21445 | 2 |
5 | en-14175 | 1 |
6 | 12236 | 1 |
7 | nomogram-a | 2 |
8 | merica | 1 |
9 | baroda | 1 |
10 | contraction-onabotulinumtoxina | 1 |
11 | ad-ssa | 4 |
12 | ward-specific | 5 |
13 | hospital-specific | 15 |
14 | ses-specific | 2 |
15 | study-specific | 113 |
16 | shrimp-allergic | 1 |
17 | macrocephalic | 1 |
18 | pedophilic | 1 |
19 | amydriatic | 2 |
20 | anatomical-therapeutic-chemical/ddd | 1 |
21 | 130-bed | 1 |
22 | two-limbed | 1 |
23 | cyclotron-produced | 1 |
24 | crp-guided | 2 |
25 | precoded | 12 |
26 | prerecorded | 13 |
27 | smooth-edged | 3 |
28 | mg-enabled | 1 |
29 | pre-designed | 34 |
30 | purpose-designed | 20 |
31 | specifically-designed | 3 |
32 | predesigned | 29 |
33 | apredesigned | 1 |
34 | pre-developed | 6 |
35 | self-developed | 18 |
36 | multiple-handicapped | 1 |
37 | blunt-tipped | 5 |
38 | publicly-registered | 1 |
39 | prestructured | 4 |
40 | nora-based | 1 |
41 | dexmedetomidine-based | 2 |
42 | social-marketing-based | 1 |
43 | nutraceutical-based | 1 |
44 | dsm-based | 3 |
45 | workstation-based | 3 |
46 | habituation-based | 1 |
47 | diameter-based | 1 |
48 | thromboelastography-based | 1 |
49 | standardised | 2,215 |
50 | semi-standardised | 9 |
51 | non-standardised | 18 |
52 | nurse-supervised | 2 |
53 | manufacturer-created | 1 |
54 | gemfibrocyl-treated | 1 |
55 | meropenem-treated | 1 |
56 | stigma-associated | 1 |
57 | cd71-mediated | 1 |
58 | self-formulated | 4 |
59 | pregenerated | 2 |
60 | child-completed | 2 |
61 | pre-piloted | 8 |
62 | comorbidity-adapted | 4 |
63 | standardized | 7,530 |
64 | nonstandardized | 20 |
65 | nonoptimized | 4 |
66 | six-field | 5 |
67 | 64-yr-old | 1 |
68 | 45-years-old | 1 |
69 | 53-day-old | 1 |
70 | rest-to-stand | 1 |
71 | two-round | 5 |
72 | drug-in-food | 1 |
73 | forced-choice | 46 |
74 | levels-of-evidence | 6 |
75 | self-made | 17 |
76 | ifosfamide-carboplatin-etoposide | 1 |
77 | n2o-free | 3 |
78 | relaxant-free | 2 |
79 | natural-language | 2 |
80 | controlled-challenge | 1 |
81 | haake | 2 |
82 | tuberculosis-like | 1 |
83 | bespoke | 23 |
84 | gt/profile | 1 |
85 | cvt/sct/ispe | 1 |
86 | block-and-release | 1 |
87 | double-pulse | 4 |
88 | four-course | 2 |
89 | midcourse | 1 |
90 | self-tabulate | 1 |
91 | munich-composite | 1 |
92 | 51-minute | 1 |
93 | 16-minute | 2 |
94 | 37-minute | 1 |
95 | galectin-9-sensitive | 1 |
96 | nonsuggestive | 2 |
97 | dynamic-ecg | 1 |
98 | 1.2-kg | 1 |
99 | 1.7-kg | 1 |
100 | fatigue-producing | 1 |
101 | dual-imaging | 1 |
102 | call.imaging | 1 |
103 | pre-teaching | 2 |
104 | blockmatching | 1 |
105 | cell-tracking | 3 |
106 | self-leveling | 3 |
107 | slow-cooling | 1 |
108 | stamping | 9 |
109 | surface-doping | 1 |
110 | 43-month | 1 |
111 | race/niti | 1 |
112 | verbal-feedback | 1 |
113 | multi-ethnical | 1 |
114 | multicultural/multiracial | 1 |
115 | non-emotional | 11 |
116 | intraexperimental | 1 |
117 | 4.46-mg/dl | 1 |
118 | takla-o'donnell | 1 |
119 | empty-and-fill | 1 |
120 | 23-item | 13 |
121 | 33-item | 12 |
122 | 15-item | 58 |
123 | nine-item | 23 |
124 | db-im | 5 |
125 | dbcg-82tm | 1 |
126 | triple-scan | 1 |
127 | artequin | 1 |
128 | t2-preparation | 2 |
129 | short-injection-duration | 1 |
130 | no-limitation | 2 |
131 | stress-redistribution-reinjection | 1 |
132 | deception-detection | 1 |
133 | activity-recognition | 1 |
134 | 'stupp | 3 |
135 | 13.4-year | 1 |
136 | 2.9-year | 2 |
137 | 2-day-longer | 1 |
138 | i-tasser | 2 |
139 | fixed-parameter | 1 |
140 | pet/ct-mr | 1 |
141 | cross-sector | 2 |
142 | senieur | 1 |
143 | 300-mas | 1 |
144 | 270-beds | 1 |
145 | limited-options | 1 |
146 | patient-access | 1 |
147 | 3-stimulus | 2 |
148 | heinous | 2 |
149 | odd-impact | 1 |
150 | voice-over-internet | 1 |
151 | pondr-fit | 3 |
152 | hpufsh-gnrhant | 2 |
153 | ich-compliant | 1 |
154 | 26-element | 3 |
155 | split-shipment | 2 |
156 | magnet-treatment | 1 |
157 | low-antigen-content | 3 |
158 | 13-point | 4 |
159 | ramp-test | 1 |
160 | milliplex | 5 |
161 | veratox | 2 |
162 | divi-emergency | 1 |
163 | turnkey | 1 |
164 | dixon-massey | 2 |
165 | laporatomy | 1 |